Русский
English
عربي
he company was involved in the development, manufacturing, and marketing of medicines across various therapeutic areas, including cardiology, oncology, immunology, dermatology, and infectious diseases.
In 2009, Schering-Plough was acquired by Merck & Co., Inc., one of the largest pharmaceutical companies in the world. Following the merger, all Schering-Plough operations and products were integrated into Merck's structure, and Schering-Plough ceased to exist as a separate entity.
Before its acquisition, Schering-Plough was known for its innovative medicines, including treatments for allergies, infectious diseases, and cardiovascular conditions. The company also had a strong focus on research and development to create new therapeutic solutions.
Key therapeutic areas that Schering-Plough had developed included:
- Cardiology – medications for heart and vascular diseases.
- Immunology – treatments for autoimmune diseases.
- Oncology – drugs for treating various types of cancer.
- Infectious diseases – antibiotics and antiviral treatments.
- Dermatology – products for skin disorders.
The merger with Merck helped strengthen research and innovation, expand the product portfolio, and improve the availability of medical solutions for patients worldwide.
